Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Colorectal carcinoma (CRC) belongs to the most common tumor entities in western countries. Circulating tumor cells (CTC) in blood of CRC patients are a powerful prognostic and predictive biomarker. However, whether CTC-associated markers can also be used for early CRC detection and discrimination from benign diseases is not known. This study investigated the presence of CTC-associated markers CK20, PLS3, LAD1, and DEFA5 in blood of patients with benign inflammatory intestinal disease (IID) and their correlation with malignancy. The detection rate of CK20 and DEFA5 significantly differed between diseased patients and healthy controls. LAD1 and PLS3 were detected in all samples with clear differences in gene expression. DEFA5 expression was higher in CRC and IID patients compared to healthy donors, while CK20 and PLS3 were lower in CRC compared to IID patients or healthy controls. Overall, all CTC-associated markers were detectable in blood of IID patients, but not correlating with inflammation severity. Finally, PLS3 emerged as a suitable marker for differentiation between malignant and non-malignant intestinal diseases or healthy controls, however its suitability for early CRC detection needs to be further validated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750406 | PMC |
| http://dx.doi.org/10.3390/cancers14010047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of the rs12617656 C/T genetic variant of the DPP4 gene with in-stent restenosis in Mexican population: a cohort study.
Arch Cardiol Mex
October 2024
Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Article Synopsis
- The study aimed to determine if five specific single nucleotide polymorphisms (SNPs) in the DPP4 gene could serve as risk markers for in-stent restenosis in patients with coronary stents.
- Genotyping was conducted on 190 patients, comparing 60 with restenosis to 130 without, using TaqMan assays.
- Findings indicated that the CC genotype of the rs12617656 SNP significantly correlates with an increased risk of restenosis, while other examined SNPs showed no difference between the two patient groups; a specific haplotype (CTC) was also linked to restenosis susceptibility.
Detection of Circulating and Disseminated Tumor Cells and Their Prognostic Value under the Influence of Neoadjuvant Therapy in Esophageal Cancer Patients.
Cancers (Basel)
March 2022
Institute for Experimental Cancer Research, Kiel University (CAU) and University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, 24105 Kiel, Germany.
Detection of circulating (CTC) or disseminated tumor cells (DTC) are correlated with negative prognosis in esophageal cancer (EC) patients. In this study, DTC- and CTC-associated markers CK20 and DEFA5 were determined by RT-PCR in EC patients and correlated with clinical parameters to determine their prognostic impact. The blood and bone marrow (BM) of 216 EC patients after tumor resection with or without neoadjuvant therapy and as control blood samples from 38 healthy donors and BM from 24 patients with non-malignant diseases were analyzed.
View Article and Find Full Text PDFDetection of Marker Associated with CTC in Colorectal Cancer in Mononuclear Cells of Patients with Benign Inflammatory Intestinal Diseases.
Cancers (Basel)
December 2021
Institute for Experimental Cancer Research, Kiel University and University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, Building U30 Entrance 1, 24105 Kiel, Germany.
Article Synopsis
- Colorectal carcinoma (CRC) is a prevalent type of cancer in western countries, and circulating tumor cells (CTCs) in patients' blood offer insights into prognosis and treatment prediction.
- The study examined CTC-associated markers (CK20, PLS3, LAD1, DEFA5) in patients with benign inflammatory intestinal disease (IID) to assess their potential for early CRC detection and differentiation from benign conditions.
- Results indicated that while DEFA5 levels were higher in CRC and IID compared to healthy individuals, CK20 and PLS3 had lower levels in CRC, suggesting that PLS3 may help distinguish between malignant and non-malignant conditions but needs further validation for early detection of CRC.
Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
Front Oncol
June 2021
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Although positive Circulating tumor cells (CTCs) status has been validated as a prognostic marker in breast cancer, the interaction between immune cells and CTCs during the progress of Epithelial-mesenchymal-transition (EMT), and the clinical implications of CTC-associated white blood cell clusters (CTC-WBC clusters) for metastatic breast cancer are largely uncharacterized.
Methods: We optimized a filter-based method combined with an RNA hybridization technique according to the epithelial- and mesenchymal-markers to analyze EMT in CTC-WBC clusters. Serial peripheral blood samples from 135 patients with Hormone receptor (HR)-positive/HER2-negative metastatic breast cancer receiving first-line chemotherapy with docetaxel plus capecitabine were prospectively collected until disease progression from Nov 2013 to March 2019.
Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.
Biomaterials
January 2016
Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, 14853, USA. Electronic address:
Circulating tumor cells (CTCs) are responsible for metastases in distant organs via hematogenous dissemination. Fundamental studies in the past decade have suggested that neutralization of CTCs in circulation could represent an effective strategy to prevent metastasis. Current paradigms of targeted drug delivery into a solid tumor largely fall into two main categories: unique cancer markers (e.
View Article and Find Full Text PDF